Delcath Systems' stock rose modestly by 2.0% following its Q1 2026 earnings, reflecting a mixed reception to solid early patient start metrics and ongoing progress in clinical trial site activations, tempered by cautious pacing on site expansions and patient enrollments.

• Activated 4 new centers in Q1, progressing toward 37 active centers by year-end and 40 centers expected by early 2027, down from previous pacing projections.
• New patient starts per site tracked slightly above Q1 2025 levels, at approximately 0.7 new patients per site per month, helping to sustain revenue growth.
• Enrollment in metastatic colorectal cancer trial remains slow with only 7 patients enrolled out of 13 active sites, though site activation and training continue to advance.
• Metastatic breast cancer trial progressing with 4 active screening sites and plans to reach 15 sites by late 2026, alongside physician education efforts to build familiarity with liver-directed therapies.
• The company is exploring expanded indications beyond colorectal and breast cancer, driven by interest in combination regimens similar to CHOPIN results.